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Aims The prognostic significance of atrial fibrillation (AF) in hospitalized patients with heart failure (HF) remains poorly
understood. To evaluate in what way AF and its different modes of presentation affect the in-hospital mortality in
patients admitted with HF.
Methods
and results
The EuroHeart Failure Survey was conducted to ascertain how hospitalized HF patients are managed in Europe. The
survey enrolled patients over a 6-week period in 115 hospitals from 24 countries. For this analysis, patients were
categorized into three groups according to the type of AF, previous AF (patients known to have had AF prior to
admission), new-onset AF (no previous AF with AF diagnosed during hospitalization), and no AF (no previous AF
and no AF during hospitalization). Clinical variables, duration of hospitalization, and in-hospital survival status were
assessed and compared among groups. Of the 10 701 patients included in the survey; 6027 (57%) had no AF,
3673 (34%) had previous AF, and 1001 (9%) had new-onset AF. Patients with new-onset AF had a longer stay in
the intensive care unit (ICU) when compared with previous AF and no AF patients (mean 2.6+5.3, 1.2+ 3.5,
and 1.5+4.1 days, respectively; P, 0.001). In-hospital mortality was higher among patients with new-onset AF
when compared with previous AF or no AF patients (12, 7, and 7% respectively; P, 0.001). After adjusting for mul-
tiple clinical variables, new-onset AF (not previous AF) was an independent predictor of in-hospital mortality (odds
ratio 1.53, 95% CI 1.1–2.0).
Conclusion In hospitalized patients with HF, new-onset AF is an independent predictor of in-hospital mortality and a longer ICU
and hospital stay.
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Introduction
The prevalence of atrial fibrillation (AF) and heart failure (HF) is
increasing due, at least in part, to the increasing proportion of
the population that is aged .60.1,2 They share common predispos-
ing factors and therefore commonly co-exist.3 Many reports have
addressed the issue of whether AF is a marker of worse prognosis
in patients suffering from HF and arrived at contradicting con-
clusions.4– 9 However, recently published sub-analyses of large ran-
domized controlled trials performed in patients with HF, and
epidemiological studies suggest that either prevalent and/or inci-
dent AF is associated with a worse long-term outcome.2,10 –14
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Hospitalization is a common event in patients with HF; it occurs
more frequently in advanced stages of the disease, it is a marker of
worse prognosis, and it is in this setting that most deaths due to
progressive HF occur. Nevertheless, there are few data on how
AF affects the in-hospital course and prognosis of patients with
HF. With this purpose in mind, the EuroHeart Failure survey data-
base was analysed in order to establish, in a ‘real-world’ population
of hospitalized HF patients, how AF affects the length of hospital
stay and in-hospital survival.
Methods
The EuroHeart Failure Survey was the second in a series of surveys
that were conducted under the umbrella of the EuroHeart Survey
Program, which aimed to investigate the implementation of treatment
guidelines in clinical practice. The design details of the EuroHeart
Failure Survey, which was undertaken between March 2000 and May
2001, were published previously.15 In short, 45 933 consecutive dis-
charges and deaths in the departments of cardiology, cardiovascular
surgery, general internal medicine, and geriatrics were screened over
a 6-week period. The survey included 115 hospitals from 24 ESC
member countries, including community hospitals and regional univer-
sity centres. Patients were enrolled if they fulfilled at least one of the
following criteria:
† a clinical diagnosis of HF during the admission;
† a diagnosis of HF recorded at any time in the last 3 years;
† administration of a loop diuretic for any reason other than renal
failure withing 24 h of death or discharge;
† pharmacological treatment for HF or ventricular dysfunction within
24 of death or discharge.
For the purpose of this analysis, patients were categorized according to
the type of AF in the following groups: (i) previous AF: those patients
who were known to have had AF prior to hospital admission (irrespec-
tive of whether it was paroxysmal, persistent or permanent), (ii) new-
onset AF: patients with no prior history of AF and who were diagnosed
as having AF during hospitalization, and (iii) no AF: patients with no
prior AF and not suffering AF during hospitalization. Clinical variables,
treatment, length of stay in the coronary care unit/intensive care unit
(CCU/ICU), length of hospitalization, hospital survival, and cause of
death were analysed according to the type of AF.
Statistical analysis
Continuous variables are described as mean values with their corre-
sponding standard deviations or as median values and corresponding
25th and 75th percentiles. Dichotomous variables are reported as
absolute numbers and percentages. To evaluate the differences in
clinical characteristics, pharmacological treatment, length of ICU and
hospital stay, and in-hospital survival between patients according to
the type of AF, x2 tests for more than two groups were applied.
ANOVA test was used for comparison of continuous variables. Multi-
variable logistic regression analysis was applied to study the relation-
ship between the type of AF and all-cause in-hospital mortality and a
long length of ICU (.75th percentile ¼ 2 days) and hospital stay
(.75th percentile ¼ 13 days). Clinically relevant variables such as
type of AF, age, gender, hypertension, diabetes, ischaemic heart
disease, valvular heart disease, prior renal insufficiency, prior stroke,
rapid AF (defined in the protocol as .120 b.p.m.), moderate or
severe left atrial dilatation (as assessed by the investigators), and
the presence of left ventricular (LV) dysfunction [ejection fraction
(EF)  50%] were forced into the regression model where no AF
was used as the reference group. We report the odds ratios (ORs)
and corresponding 95% confidence intervals (CIs). All calcu-
lations were performed using SPSS 14.0 software package. For all
tests, P  0.05 or less (two-sided) was considered as statistically
significant.
Results
Of the 10701 patients included in the survey, 6027 (57%) had no
AF prior to or during hospitalization (no AF group), 3673 (34%)
were known to have had AF prior to admission (previous AF
group), and 1001 (9%) had no AF before admission but were
reported to have AF during admission (new-onset AF group)
(Table 1). Patients with no AF were younger than patients with
AF (irrespective of type) (70+ 13 vs. 73+12; P, 0.001). The
proportion of patients with a reduced LVEF was similar
between groups but more patients with prior AF or new-onset
AF had moderate or severe left atrial dilatation as compared to
no AF patients (28, 17, and 13% respectively; P, 0.001). Rapid
AF was more frequent in the new-onset AF group when com-
pared with the previous AF group (77 vs. 27%; P, 0.001).
Patients with new-onset AF were more frequently treated
in-hospital with anti-arrhythmic drugs than those with previous
AF or no AF (32, 22, and 7%, respectively; P, 0.001). Digitalis
and anticoagulation use was higher in patients with AF irrespec-
tive of the type.
Duration of intensive care unit stay and
hospitalization
The mean length of stay in the ICU for the entire population was
1.5+ 4.1 days. Patients with new-onset AF had a significantly
longer stay in the ICU when compared with previous AF and no
AF patients (2.6+ 5.3, 1.2+3.5, and 1.5+4.1 days respectively;
P, 0.001) (Table 2). When adjusting for multiple clinical variables,
new-onset AF (OR 1.45, 95% CI 1.2–1.8) and rapid AF (OR 1.84,
95% CI 1.5–2.1) were independent predictors of a longer stay in
the ICU (Figure 1). However, previous AF was not predictive of
a longer ICU stay.
The mean amount of days hospitalized for the entire population
was 12+12. Patients with new-onset AF were admitted longer
than those with previous AF and no AF (14+12, 13+12, and
12+12 days, respectively; P, 0.001) (Table 2). After adjusting
for multiple clinical variables, new-onset AF (OR 1.46, 95% CI
1.2–1.7) was an independent predictor of a longer hospitalization
(Figure 2).
In-hospital mortality
There were 791 deaths (7%) during admission. In-hospital mor-
tality was higher among patients with new-onset AF when com-
pared with previous or no AF patients (12, 7, and 7%,
respectively; P, 0.001). New-onset AF and rapid AF (but not pre-
vious AF or the presence of AF irrespective of the type) were pre-
dictors of mortality in the univariate analysis. When introducing
these variables in a multiple logistic regression model, new-onset
AF (OR 1.53, 95% CI 1.1–2.0) remained an independent predictor
of in-hospital mortality (Figure 3). Left atrial dilatation was also
independently associated to a worse prognosis (OR 1.31, 95% CI
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1.1–1.4) and rapid AF showed a tendency towards an increased
mortality. However, the presence of previous AF did not predict
the in-hospital survival.
Mode of death
Overall, the predominant causes of death were worsening HF
(32%) followed by pulmonary oedema (24%) and other
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Table 2 In-hospital evolution
No AF (n 5 6027) Previous AF (n 5 3673) New-onset AF (n5 1001) P-valuea
Days in ICU or CCU
Mean (SD) 1.5 (4.1) 1.2 (3.5) 2.6 (5.3) ,0.001
Median (IQR) 0 (0–1) 0 (0–0) 0 (0–3) ,0.001
Days hospitalized
Mean (SD) 12 (12) 13 (12) 14 (12) ,0.001
Median (IQR) 9 (5–15) 9 (6–16) 11 (7–17) ,0.001
In-hospital mortality 419 (7%) 249 (7%) 123 (12%) ,0.001
ax2 for more than two groups for categorical variables and ANOVA for continuous variables.
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Table 1 Clinical characteristics and pharmacological treatment of patients enrolled in the EuroHeart Failure Survey by
type of atrial fibrillation (n5 10 701)
No AF (n5 6027) Previous AF (n5 3673) New onset AF (n5 1001) P-valuea
Mean age in years (SD) 70 (13) 73 (12) 73 (12) ,0.001
Male 3260 (54%) 1859 (51%) 523 (52%) 0.005
Clinical characteristics
Rapid AF (.120 beats/min) 0 (0%) 1000 (27%) 768 (77%) ,0.001
Ischaemic heart disease 3921 (65%) 2070 (56%) 563 (56%) ,0.001
Acute coronary syndromes 1192 (30%) 363 (18%) 212 (38%) ,0.001
Prior revascularization 935 (16%) 423 (12%) 98 (10%) ,0.001
EF known 3739 (54%) 2484 (36%) 672 (10%) ,0.001
Mean EFb (SD) 0.42 (0.15) 0.44 (0.16) 0.45 (0.15) ,0.001
LVSD (EF  45%)b 2482 (66%) 1570 (63%) 419 (62%) 0.013
Moderate/severe LA dilatation 788 (13%) 1023 (28%) 167 (17%) ,0.001
Not reported 3269 (54%) 1702 (46%) 507 (51%) ,0.001
Valvular heart disease 649 (11%) 688 (19%) 142 (14%) ,0.001
Prior stroke 794 (13%) 665 (18%) 125 (13%) ,0.001
Prior renal insufficiency 647 (11%) 477 (13%) 83 (8%) ,0.001
Diabetes 1715 (29%) 944 (26%) 221 (22%) ,0.001
Hypertension 3202 (53%) 1973 (54%) 504 (50%) 0.165
Pulmonary disease 1830 (30%) 1244 (34%) 303 (30%) 0.001
BMI (mean, SD) 27.1 (5.2) 26.8 (5.2) 26.8 (5.2) 0.056
Medical treatment during hospital admission
Anti-arrhythmic drugs 437 (7%) 822 (22%) 315 (32%) ,0.001
Antiplatelets 3461 (57%) 1604 (44%) 528 (53%) ,0.001
Anticoagulants 1996 (33%) 1999 (54%) 567 (57%) ,0.001
ACE-I or ARB 3933 (65%) 2445 (67%) 615 (61%) 0.01
Beta-blockers 2385 (40%) 1199 (33%) 360 (36%) ,0.001
Digoxin 1236 (21%) 2068 (56%) 521 (52%) ,0.001
Diuretics 5119 (85%) 3302 (90%) 876 (88%) ,0.001
ACE-I, angiotensin-converting enzyme-inhibitors; ARB, angiotensin II receptor blockers; AF, atrial fibrillation; EF, ejection fraction; LA, left atrial.
ax2 for more than two groups for categorical variables and ANOVA for continuous variables.
bBased on those patients in whom EF was known.
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Figure 2 Independent predictors of length of hospitalization.
Figure 1 Independent predictors of length of stay in the CCU–ICU.
Figure 3 Independent predictors of in-hospital mortality.
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cardiovascular causes (18%). No differences were observed
regarding causes of death between the different groups (Table 3).
Discussion
This study shows that new-onset AF is common in patients hospi-
talized with HF, occurring in 9% of admissions, and that it is associ-
ated with a higher in-hospital mortality, conferring a 53% increased
risk independent of other relevant clinical variables such as age,
sex, LVEF, and renal function. In patients with new-onset AF,
both hospital and ICU stays were longer, even after adjusting for
other clinically relevant variables. Our findings also show that
having had AF prior to admission did not affect hospital survival
or length of stay.
Middlekauf et al.4 reported, in a cohort of 390 patients, that
1-year mortality was higher in patients with HF if they had AF
but a report from the Vasodilator in Heart Failure Trials
(V-HeFT) suggested that AF was not associated with a worse sur-
vival.8 Subsequently, Stevenson et al.9 compared the prognosis of
patients with and without AF evaluated for heart transplantation
between 1985 and 1989 with those evaluated between 1990 and
1993. They reported that AF was associated with a worse
outcome only during the first time period and suggested that
changes in treatment, such as the use of ACE-inhibitors and a
reduction in the use of class I anti-arrhythmic drugs, might
account for this observation. In a subgroup of 409 patients in
the PRIMIE-II study, Crijns et al.5 showed that patients with AF
had a higher mortality than patients in sinus rhythm but this
could be accounted for by differences in age, disease severity,
and co-morbidity. Neither the presence of AF nor the develop-
ment of AF was independent predictor of mortality during long-
term follow-up. A retrospective analysis of the SOLVD trials
showed that in a much larger cohort of 6517 patients (419 with
AF) AF was independently associated with a 34% increase in
overall mortality after a mean follow-up of 33 months.6
Other trials also assessed the impact of new-onset AF in this
patient population and results are more consistent in establishing
the role of new-onset AF as a marker of poor outcome.7,16 –19
In a post hoc analysis of the COMET trial, the authors report
that baseline AF did not independently predict mortality;
however, onset of AF during the study was independently associ-
ated with a worse survival during follow-up (RR 1.9).12 The
CHARM studies showed that new-onset AF was an independent
predictor of adverse outcome in patients with depressed or
preserved LV systolic function (OR 2.57 in preserved and 1.85
with reduced LVEF).11 In agreement with these findings, the DIG
investigators reported that the development of new-onset
supraventricular arrhythmias was independently associated with a
reduced survival during the follow-up (HR ¼ 2.45).10
A recent report from the Framingham Heart Study evaluated
the time relation between the onset of HF and AF.13 It showed
that patients with established HF who later on developed AF
carried an increased risk of death (RR 1.6). Other observational
studies performed in hospitalized HF patients show that the occur-
rence of AF is associated with a worse long-term prognosis.7
It is unclear whether chronic AF has an adverse impact on prog-
nosis in patients with well-established HF who receive the high
quality of management expected in clinical trial centres.
However, new-onset AF appears to predict an adverse outcome
during long-term follow-up.
Role of atrial fibrillation during heart
failure hospitalization
Hospitalization is a turning point in the natural history of HF.
Patients with chronic HF who require hospitalization have a
worse prognosis and many will die during the first or a subsequent
admission. Accordingly, it is important to understand the role that
AF plays during this period. We showed in a broad population of
patients hospitalized for or with HF that new-onset AF (but not
prior AF) adversely affected hospital survival, despite the fact
that patients with new-onset AF had an apparently lower risk
profile than those with previous AF or no AF. Patients with new-
onset AF were less likely to have renal dysfunction, diabetes,
hypertension, or a previous stroke. Nonetheless, mortality
among new-onset AF patients was twice as high as that of patients
in the other groups. Pozzoli et al.16 showed that the development
of AF was associated with a sudden reduction in cardiac index, rise
in filling pressures, and a worse prognosis shortly after its initiation,
but this did not persist after longer follow-up. Therefore it is poss-
ible that increased mortality is due to the adverse consequences of
new-onset AF on cardiac function. However, it is also possible that
the cause of new-onset AF is also the reason for the increase in
mortality, making AF a marker but not a mediator of mortality.
The causes leading to death in the patients with new-onset AF
were predominantly related to decompensated HF (Table 3).
The mechanisms leading to mortality in recent-onset AF patients
are probably different (predominantly haemodynamic) than
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Table 3 Mode of death by type of atrial fibrillationa
No AF (n5 419) Previous AF (n5 249) New-onset AF (n5 123) P-valueb
Worsening heart failure 141 (34%) 71 (29%) 42 (34%) ,0.001
Pulmonary oedema 99 (24%) 58 (23%) 34 (28%) ,0.001
Stroke 17 (4%) 27 (11%) 8 (7%) ,0.001
Other cardiovascular cause 79 (19%) 35 (14%) 27 (22%) ,0.001
Non-cardiovascular cause 71 (17%) 40 (16%) 25 (20%) ,0.001
aData collectors could choose more than one cause.
bx2 for more than two groups for categorical variables and ANOVA for continuous variables.
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those in long standing forms of the arrhythmia (stroke, progressive
remodelling, etc.). Furthermore, our study suggests that those HF
patients who go on to develop persistent forms of AF are probably
those who were able to survive the initial stages of the arrhythmia.
Study limitations
There are certain limitations regarding this study that should be
considered when interpreting the results. This survey was not con-
ducted with the purpose of evaluating the relation of AF occur-
rence and hospitalization prognosis. Consequently, relevant
information regarding specific characteristics of AF and manage-
ment of the arrhythmia during admission was not accounted for.
It should also be noted that categorization according to the type
of AF was retrospectively performed and thus subject to misclassi-
fication. However, studying large sample sizes and screening for
consecutive patients provide protection against random and sys-
tematic error, respectively. Furthermore, clinical characteristics
of the different groups seem to be representative of what would
be expected; for example: the presence of left atrial dilation was
higher in previous AF than in new-onset AF or no AF, prior
stroke was more common in patients with AF than in no AF, anti-
arrhythmic drug therapy was more common in patients suffering
from AF than those without it, etc.
Even though surveys attempt to make a realistic description of a
certain clinical situation, it could be argued that a potential limit-
ation of this study is the heterogeneity of the population included
(patients were recruited from different departments and were HF
was not always the primary diagnosis) that may not be completely
representative of the HF population. However, it was not the
objective of this survey to restrict the enrolment to the HF popu-
lation usually included in clinical trials.
Our results suggest that the development of AF in hospitalized
patients with HF is a relevant clinical event that should be ade-
quately approached. Although it should be prospectively deter-
mined, measures aiming at preventing the occurrence of AF
during admission and appropriate and expeditious treatment of
these episodes seem warranted in order to improve the survival
of hospitalized HF patients.
It should be borne in mind that in an important proportion of
patients no echocardiogram was performed during or prior to
the index admission; therefore, information regarding EF and left
atrial dimension should be cautiously interpreted accordingly.
Conclusion
In hospitalized patients with HF, the occurrence of new-onset AF
was associated with a longer stay in the ICU, a longer hospitaliz-
ation, and higher in-hospital mortality independently from other
relevant clinical variables.
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A 73-year-old man presented to the
emergency department with dyspnea of
2 days duration. Auscultation of the precor-
dium was notable for a grade 2/6 systolic
murmur. Echocardiography revealed a highly
impaired left ventricular function and a calci-
fied aortic valve stenosis with a mean
pressure gradient of 25 mmHg and a valve
area of 0.8 cm2. Eye-catching was a thickened
mid-ventricular and apical myocardium with a
spongy appearance. On magnetic resonance
imaging (MRI) multiple, prominent muscular
trabeculations of the left ventricular myocar-
dium (white arrows) with deep intertrabecu-
lar recesses were evident (Panel A, LV: left
ventricle, LA: left atrium). These findings
were consistent with non-compaction cardio-
myopathy with accompanying low-gradient
aortic valve stenosis. The patient underwent
mechanical aortic valve replacement, during
which the spongy left ventricular myocar-
dium was visualized by video endoscopy
(Panel B). The histological workup of an
endomyocardial biopsy specimen showed
irregular heart muscle fibres with vacuolar changes and large chromatin-dense nuclei as well as moderate interstitial fibrosis (Panel C,
haematoxylin and eosin staining, magnification: original 20). The patient made a full recovery and was discharged on heart failure
medication and oral anticoagulation. Screening of first-degree relatives by MRI revealed left ventricular non-compaction with a pre-
served ejection fraction in the patient’s asymptomatic son (Panel D, LV: left ventricle, LA: left atrium).
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